← Back to headlines
Biogen Acquires Apellis for $5.6 Billion to Enhance Rare Disease Pipeline
Biogen has announced the acquisition of Apellis for $5.6 billion, a move aimed at strengthening its pipeline for rare disease treatments.
1 Apr, 11:36 — 1 Apr, 11:36
Sources
Showing 1 of 1 sources
Related Stories
HDFC Bank CEO Sashidhar Jagdishan to Step Down in October
2h ago
FSSAI Bans Everest and Laljee Godhoo From Selling Substandard Hing Powder
3h ago
UAE Central Bank Launches Probe Into Banque Misr Over US Money Laundering Warnings
3h ago
S&P, Nasdaq end lower after Fed Chair Warsh reaffirms inflation fight - Reuters
4h ago